All In Biotech

NDA 209022 · Paratek Pharms

Xhance

Fluticasone Propionate · Nasal

Last checked: Nov 20, 2026Latest source record: Mar 15, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2017

Sep 18, 2017

Approved uses

2

Original approval plus efficacy supplements

Registered trials

738

240 Phase 3, 19 recruiting

FAERS reports

33,357

18,259 serious, 1,786 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Oct 23, 2026.

XHANCE is a corticosteroid indicated for the treatment of: Chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. ( 1.1 ) Chronic rhinosinusitis without nasal polyps (CRSsNP) in adults. ( 1.2 ) 1.1 Chronic Rhinosinusitis with Nasal Polyps XHANCE is indicated for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults. 1.2 Chronic Rhinosinusitis without Nasal Polyps XHANCE is indicated for the treatment of chronic rhinosinusitis without nasal polyps (CRSsNP) in adults.

Mechanism: Fluticasone propionate is a synthetic trifluorinated corticosteroid with anti-inflammatory activity. Fluticasone propionate has been shown in vitro to exhibit a binding affinity for the human glucocorticoid receptor that is 18 times that of dexamethasone, almost twice that of beclomethasone-17-monopropionate (BMP), the active metabolite of beclomethasone dipropionate, and over 3 times that of budesonide. Data from the McKenzie vasoconstrictor assay in man are consistent with these results. The clinical significance of these findings is unknown. The precise mechanism through which fluticasone...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 15, 2024 Supplement 19 · Efficacy LetterLabel
  • Sep 18, 2017 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
1 products under this application
  • XHANCE · FLUTICASONE PROPIONATE 0.093MG/SPRAY · SPRAY, METERED, NASAL · Prescription

Clinical trials

Interventional ClinicalTrials.gov studies with "Fluticasone Propionate" as an intervention, any sponsor and status, largest first.

All 738 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • dyspnoea2,573
  • drug ineffective2,569
  • headache2,517
  • fatigue2,242
  • off label use2,043
  • pain1,947
  • nausea1,931
  • cough1,899
  • asthma1,729
  • diarrhoea1,694
  • product dose omission issue1,620
  • dizziness1,510

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004383
2005329
2006341
2007414
2008430
2009383
2010584
2011917
20121,014
2013372
2014484
20151,120
20161,530
20171,239
20181,793
20192,156
20202,510
20212,234
20222,495
20232,949
20243,456
20253,669
20262,554

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Xhance (Fluticasone Propionate)

2024 spending

$19.9M

Beneficiaries

8,766

25,053 claims

Per beneficiary

$2,276

$37.72 per unit

View as table
YearSpending
2020$8,228,875
2021$11,979,404
2022$15,573,543
2023$18,483,355
2024$19,948,163

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,190 on PubMed

Sponsor: Paratek Pharms

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.